Compare VanEck Australian Floating Rate ETF (FLOT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Illumina, Inc. — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93, while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| FLOT | ILMN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $205.10 |
52-Week Low | $50.72 | $91.00 |
Market Cap | — | $28.96B |
Enterprise Value | — | $30.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT, the iShares Floating Rate Bond ETF, trades at $50.93, showing minimal daily movement. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights its role as a potential hedge against rising interest rates, with a focus on high credit quality and a 4.0% SEC yield. Dividend payments are consistent, with recent distributions around $0.17-$0.18 per share.
The outlook for FLOT is cautiously positive if the Federal Reserve raises rates, as its floating rate structure could benefit income growth. Risks include credit quality deterioration and persistent inflation without Fed action. Analyst sentiment is generally neutral, viewing it as a stable short-term cash alternative rather than a growth vehicle.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
